Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of L
Go back to Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of L| (NASDAQ: AKRO) | Delayed: 54.74 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $54.74 | 52 Week High | $ | |||
| Open | $54.74 | 52 Week Low | $ | |||
| Day High | $54.74 | P/E | N/A | |||
| Day Low | $54.74 | EPS | $ | |||
| Volume | 2,530 | |||||
